Eisai R&D Day Highlights Diverse Pipeline Fueled By Large, Small Molecules
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Japanese pharma company Eisai aims to file its toll-like receptor 4 antagonist eritoran NDA for the treatment of severe sepsis simultaneously in U.S., Europe and Japan in fiscal year 2009, the company announced July 17 at its R&D Day in Tokyo
You may also be interested in...
Asia Spotlight: Ascendancy Healthcare CEO Sandy Zweifach On The Gap In China
Seeing a gap between the large infrastructure being built in China by multinational and domestic companies, Ascendancy hopes to be an interface to help China access drugs from the West.
Ascendancy Healthcare CEO Sandy Zweifach On The Gap In China: An Interview With PharmAsia News (Part 2 of 2)
Seeing a gap between the large infrastructure being built in China by multinational and domestic companies, Ascendancy hopes to be an interface to help China access drugs from the West.
Ascendancy Healthcare CEO Sandy Zweifach On The Gap In China: An Interview With PharmAsia News (Part 1 of 2)
Seeing a gap between the large infrastructure being built in China by multinational and domestic companies, Ascendancy hopes to be an interface to help China access drugs from the West.